Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31523472 | 0.90 | KDM4E (0.45) | CFTRMAPTTSHRKDM4EGAA | |
| SCHEMBL31522914 | 0.83 | KDM4E (0.42) | MAPTKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL31523547 | 0.78 | ALDH1A1 (0.41) | CFTRMAPTTSHRKDM4EGAA | |
| SCHEMBL31523343 | 0.77 | MAPT (0.39) | CFTRMAPTTSHRKDM4EGAA | |
| SCHEMBL23043656 | 0.77 | TSHR (0.42) | CFTRMAPTTSHRKDM4EGAA | |
| SCHEMBL30391898 | 0.77 | TSHR (0.42) | CFTRMAPTTSHRKDM4EGAA | |
| SCHEMBL31523406 | 0.72 | CFTR (0.50) | CFTRMAPTTSHRKDM4EGAA | |
| SCHEMBL31523480 | 0.70 | KDM4E (0.41) | MAPTKDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL15038313 | 0.70 | KDM4E (0.72) | CFTRMAPTTSHRKDM4EGAA | |
| SCHEMBL7850933 | 0.69 | KDM4E (0.47) | CFTRMAPTTSHRKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | CFTR 787/4885MAPT 4614/4885TSHR 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.